Cannabis and Parkinson’s Disease

Parkinson’s illness, likewise referred to as PD, is the second most common neurodegenerative problem. The condition is identified by a loss of dopamine-producing nerve cells in the substantia nigra, which is an area of the mind accountable for activity. Marijuana, specifically CBD, has revealed promise in dealing with a few of the signs of PD. In this video we will certainly define Parkinson’s disease and cannabis, explain how cannabis can assist with PD, and physician perspectives on suggesting cannabis.

This video was produced by Demystifying Medicine trainees Simran Matharu, Mahek Minhas and Micaela McNulty in partnership with the McMaster Demystifying Medicine Program

Copyright McMaster University 2021

For additional information browse through:

https://www150.statcan.gc.ca/n1/pub/82-003-x/2014011/article/14112-eng.htm

Time Stamps:

Introduction/What is Parkinson’s Disease? → 00:00 – 01:23

What is Cannabis? → 01:24 – 02:34

Just How Can Cannabis Help With Parkinson’s? → 02:35 – 05:09

Doctor Perspectives → 05:10 – 07:19

Verdict → 07:20 – 07:52

Recommendations:

Bega, D., Simuni, T., Okun, M. S., Chen, X., & Schmidt, P. (2016 ). Medical cannabis for Parkinson’s illness: Practices, beliefs, and perspectives amongst suppliers at national Parkinson Foundation facilities of quality. Motion Disorders Clinical Practice, 4( 1 ), 90-95.

Benner, E. J., Banerjee, R., Reynolds, A. D., Sherman, S., Pisarev, V. M., Tsiperson, V., Nemachek, C., Ciborowski, P., Przedborski, S., Mosley, R. L., & Gendelman, H. E. (2008 ). Nitrated alpha-synuclein immunity increases deterioration of nigral dopaminergic nerve cells. PloS one, 3( 1 ), e1376.

Clapper, J. R., Mangieri, R. A., & Piomelli, D. (2009 ). The endocannabinoid system as a target for the therapy of marijuana dependence. Neuropharmacology, 56, 235– 243.

de Lau, L. M., & Breteler, M. M. (2006 ). Public health of Parkinson’s condition. The Lancet Neurology, 5( 6 ), 525– 535.

Edelstein, O. E., Wacht, O., Isralowitz, R., Reznik, A., & Bachner, Y. G. (2020 ). Ideas and also mindsets of graduate gerontology pupils concerning medical cannabis use for Alzheimer’s and Parkinson’s condition. Complementary Therapies in Medicine, 52, 102418.

Gardiner, K. M., Singleton, J. A., Sheridan, J., Kyle, G. J., & Nissen, L. M. (2019 ). Wellness professional beliefs, understanding, and issues surrounding medicinal cannabis– An organized evaluation. PLOS ONE, 14( 5 ), e0216556.

Hauser, R. A., Rascol, O., Korczyn, A. D., Jon Stoessl, A., Watts, R. L., Poewe, W., De Deyn, P. P., & Lang, A. E. (2007 ). Ten-year follow-up of Parkinson’s condition people randomized to preliminary therapy with ropinirole or levodopa. Activity problems: main journal of the Movement Disorder Society, 22( 16 ), 2409– 2417.

Jankovic, J. (2008 ). Parkinson’s illness: Clinical functions and also medical diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, 79( 4 ), 368– 376.

Klein, C., Karanges, E., Spiro, A., Wong, A., Spencer, J., Huynh, T., Gunasekaran, N., Karl, T., Long, L. E., Huang, X.-F., Liu, K., Arnold, J. C., & McGregor, I. S. (2011 ). Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioral effects as well as modifies THC pharmacokinetics throughout chronic as well as acute therapy in teenage rats. Psychopharmacology, 218( 2 ), 443– 457.

Lang, A. E., & Lozano, A. M. (1998 ). Parkinson’s Disease. New England Journal of Medicine, 339( 16 ), 1130– 1143.

Laun, A. S., & Song, Z. H. (2017 ). GPR3 and also GPR6, novel molecular targets for cannabidiol. Biophysical and biochemical research interactions, 490( 1 ), 17– 21.

Marras, C., Beck, J. C., Bower, J. H., Roberts, E., Ritz, B., Ross, G. W., Abbott, R. D., Savica, R., Van Den Eeden, S. K., Willis, A. W., & Tanner, C. (2018 ). Frequency of Parkinson’s disease throughout North America. Npj Parkinson’s Disease, 4( 1 ), 21.

Nutt J. G. (2000 ). Response to L-dopa in PD: the lengthy as well as the except it. Neurology, 54( 10 ), 1884– 1885. https://doi.org/10.1212/wnl.54.10.1884

Oeckl, P., Hengerer, B., & Ferger, B. (2014 ). G-protein coupled receptor 6 shortage modifies striatal dopamine as well as cAMP focus and decreases dyskinesia in a computer mouse version of Parkinson’s disease.

Extreme Spasticity. (2020 ). https://lioresal.com/severe-spasticity/.

Venderová, K., Růzicka, E., Vorísek, V., & Visnovský, P. (2004 ). Survey on marijuana usage in Parkinson’s illness: subjective renovation of motor signs. Activity disorders: main journal of the Movement Disorder Society, 19( 9 ), 1102– 1106. https://doi.org/10.1002/mds.20111

Wang, M., Wang, Y.-H., Avula, B., Radwan, M. M., Wanas, A. S., Mehmedic, Z., van Antwerp, J., ElSohly, M. A., & Khan, I. A. (2017 ). Measurable Determination of Cannabinoids in Cannabis and also Cannabis Products Using Ultra-High-Performance Supercritical Fluid Chromatography and Diode Array/Mass Spectrometric Detection. Journal of Forensic Sciences, 62( 3 ), 602– 611. https://doi.org/10.1111/1556-4029.13341